The TVC yields ranged from 2.7 × 109 to 77.1 × 109 cells, encompassing the expected target dose range (1 × 109–150 × 109 cells), while tumor cell impurities (TROP2+/EPCAM+) remained minimal (<0.1%). The gene discussed is TACSTD2; the disease is neoplasm.